The developer of epigenetic medicine, based on Whitehead Institute research, pulled in funding through a round led by founding investor Flagship Pioneering.

Omega Therapeutics, a US-based epigenetic medicine developer utilising research from Whitehead Institute, closed its series C round at $126m on Tuesday. Company builder and venture capital firm Flagship Pioneering led the round, which also featured investment and financial services firm, Fidelity, Invus, Cowen, Point72, Logos Capital, Mirae Asset Capital, funds and accounts managed by BlackRock…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.